Showing 4911-4920 of 9576 results for "".
- POSITIVE: Tildrakizumab Shows Effectiveness in Psoriasis Patients at 52 Weekshttps://practicaldermatology.com/news/positive-tildrakizumab-shows-effectiveness-psoriasis-patients-52-weeks/2467194/New one-year data presented at the International Federation of Psoriasis Associations (IFPA) Conference 2024 showed that tildrakizumab (Illumetri, Almirall) was effective at restoring and maintaining wellbeing of patients with moderate-to-severe psoriasis. Researchers for the POSITIVE st
- Event Promotes Anti-Itch Cream for Stopping Pesky Bugs From Disrupting Summer Funhttps://practicaldermatology.com/news/event-promotes-anti-itch-cream-stopping-pesky-bugs-disrupting-summer-fun/2467168/Summer is in full swing and as patients spend more time outdoors, bug bites and other skin irritants will find a way to disrupt the fun.
- Smoking, BMI, and Age Affect Biologic Outcomes in Psoriasis: Analysishttps://practicaldermatology.com/news/smoking-bmi-and-age-affect-biologic-outcomes-psoriasis-analysis/2467138/A new systematic review and meta-analysis revealed a number of factors that can make patients with psoriasis have a poorer response to biologics. Researchers for the study used data from PubMed, Embase, and Web of Science reporting treatment outcomes using Psoriasis Area and Severity Ind
- FDA Approves Gel for Axillary Hyperhidrosishttps://practicaldermatology.com/news/fda-approves-gel-axillary-hyperhidrosis/2467109/The US Food and Drug Administration (FDA) has approved a new prescription gel used to treat axillary hyperhidrosis (excessive underarm sweating) in adults and children 9 and older, manufacturer Botanix Pharmaceuticals announced. Sofdra (sofpironium) is the first chemical entity approved b
- Olympian Suni Lee Speaks on AD Panelhttps://practicaldermatology.com/news/olympian-suni-lee-speaks-ad-panel/2467107/Gymnast Suni Lee plans to defend her Olympic gold medal this summer in Paris, but first, she took time to participate in a panel discussion on a topic that has plagued her for several years: atopic dermatitis, or eczema. The 21-year-old American joined National Eczema Association President
- Survey: 43% With Acne Worry They'll Never Have Clear Skinhttps://practicaldermatology.com/news/survey-43-acne-worry-theyll-never-have-clear-skin/2467063/Ninety percent of acne sufferers experience daily insecurities related to their acne, and 43% worry they will never have clear skin, according to a new survey conducted by Cutera, Inc. June is Acne Awareness Month, and Cutera said in a press release that the findings of the survey “highli
- Moderate-to-Severe AA Linked to AD Comorbidityhttps://practicaldermatology.com/news/moderate-severe-aa-linked-ad-comorbidity/2467042/Patients with moderate-to-severe alopecia areata (AA) had higher prevalence and incidence of atopic dermatitis (AD) comorbidity and higher prevalence of moderate-to-severe AD than those with mild AA in a study presented this month at the Revolutionizing Alopecia, Vitligo, and Eczema (RAVE) Confer
- Sustained Efficacy Following Treatment With Lebrikizumabhttps://practicaldermatology.com/news/sustained-efficacy-following-treatment-lebrikizumab/2467017/A subset of moderate-to-severe atopic dermatitis (AD) patients who were randomly withdrawn from lebrikizumab maintained a stable EASI 90 response up to Week 52 with negligible remaining lebrikizumab serum concentrations, according to research presented at the Revolutionizing Atopic Dermatitis (RA
- FDA Gives Green Light to InnoCare's Clinical Trial of TYK2 Inhibitor ICP-332 for ADhttps://practicaldermatology.com/news/fda-gives-green-light-innocares-clinical-trial-tyk2-inhibitor-icp-332-ad/2467004/InnoCare Pharma announced that the FDA has cleared its investigational new drug (IND) application for its novel TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332. ICP-332 is a potent and selective TYK2 inhibitor. It achieved multiple efficacy endpoints in the China phase 2 study for the treatmen
- FDA-Cleared Fractional Laser for Hair Loss Now Availablehttps://practicaldermatology.com/news/fda-cleared-fractional-laser-hair-loss-now-available/2467000/The only US Food and Drug Administration-cleared fractional laser for safe, effective, and natural hair loss treatment is now available on the US market with the launch of FoLix from Lumenis Be. Ltd. Utilizing fractional laser and proprietary technology tailored for hair, FoLix offers res